Director/PDMR Shareholding

RNS Number : 7232P

Mediclinic International plc

30 May 2018

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

30 May 2018

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes retained the totality of the shares at the time but has now disposed of them to cover personal tax liabilities. Mr Meintjes continues to hold 123 900 shares in the Company.

The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Mr Daniël Petrus Meintjes
2.	Reason for the notification
a)	Position / status	Chief Executive Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares awarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 110.01 per share 17 423
d)	Aggregated information Aggregated volume Price	17 423 ZAR 110.01
e)	Date of the transaction	24 May 2018
f)	Place of the transaction	Johannesburg Stock Exchange
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Sale of shares awarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017
c)	Price(s) and volume(s)	Price(s) Volume(s) ZAR 107.01 per share 32 000
d)	Aggregated information Aggregated volume Price	32 000 ZAR 107.01
e)	Date of the transaction	25 May 2018
f)	Place of the transaction	Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBXGDUSSXBGIG